These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 21209903)

  • 21. Targeting the PI3K/Akt/mTOR pathway with the pan-Akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases.
    Ippen FM; Grosch JK; Subramanian M; Kuter BM; Liederer BM; Plise EG; Mora JL; Nayyar N; Schmidt SP; Giobbie-Hurder A; Martinez-Lage M; Carter SL; Cahill DP; Wakimoto H; Brastianos PK
    Neuro Oncol; 2019 Nov; 21(11):1401-1411. PubMed ID: 31173106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Four-and-a-half-LIM protein 1 down-regulates estrogen receptor α activity through repression of AKT phosphorylation in human breast cancer cell.
    Zhang F; Feng F; Yang P; Li Z; You J; Xie W; Gao X; Yang J
    Int J Biochem Cell Biol; 2012 Feb; 44(2):320-6. PubMed ID: 22094188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
    Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
    PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical, diagnostic significance and theranostic interest of PIK3CA gene mutations in breast cancer].
    Harlé A; Lion M; Lozano N; Merlin JL
    Bull Cancer; 2013 Oct; 100(10):947-54. PubMed ID: 24077110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
    Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
    Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oncogenic PI3K and its role in cancer.
    Samuels Y; Ericson K
    Curr Opin Oncol; 2006 Jan; 18(1):77-82. PubMed ID: 16357568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
    Kalinsky K; Heguy A; Bhanot UK; Patil S; Moynahan ME
    Breast Cancer Res Treat; 2011 Sep; 129(2):635-43. PubMed ID: 21617917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness.
    Tserga A; Chatziandreou I; Michalopoulos NV; Patsouris E; Saetta AA
    Virchows Arch; 2016 Jul; 469(1):35-43. PubMed ID: 27059323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling.
    Abramson VG; Cooper Lloyd M; Ballinger T; Sanders ME; Du L; Lai D; Su Z; Mayer I; Levy M; LaFrance DR; Vnencak-Jones CL; Shyr Y; Dahlman KB; Pao W; Arteaga CL
    Breast Cancer Res Treat; 2014 Jun; 145(2):389-99. PubMed ID: 24722917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PIK3R1 underexpression is an independent prognostic marker in breast cancer.
    Cizkova M; Vacher S; Meseure D; Trassard M; Susini A; Mlcuchova D; Callens C; Rouleau E; Spyratos F; Lidereau R; Bièche I
    BMC Cancer; 2013 Nov; 13():545. PubMed ID: 24229379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PIK3CA mutation associates with improved outcome in breast cancer.
    Kalinsky K; Jacks LM; Heguy A; Patil S; Drobnjak M; Bhanot UK; Hedvat CV; Traina TA; Solit D; Gerald W; Moynahan ME
    Clin Cancer Res; 2009 Aug; 15(16):5049-59. PubMed ID: 19671852
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PIK3CA alterations in Middle Eastern ovarian cancers.
    Abubaker J; Bavi P; Al-Haqawi W; Jehan Z; Munkarah A; Uddin S; Al-Kuraya KS
    Mol Cancer; 2009 Jul; 8():51. PubMed ID: 19638206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer.
    Da Silva L; Simpson PT; Smart CE; Cocciardi S; Waddell N; Lane A; Morrison BJ; Vargas AC; Healey S; Beesley J; Pakkiri P; Parry S; Kurniawan N; Reid L; Keith P; Faria P; Pereira E; Skalova A; Bilous M; Balleine RL; Do H; Dobrovic A; Fox S; Franco M; Reynolds B; Khanna KK; Cummings M; Chenevix-Trench G; Lakhani SR
    Breast Cancer Res; 2010; 12(4):R46. PubMed ID: 20604919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells.
    Ford CE; Ekström EJ; Andersson T
    Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3919-24. PubMed ID: 19237581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer.
    Bhat-Nakshatri P; Wang G; Appaiah H; Luktuke N; Carroll JS; Geistlinger TR; Brown M; Badve S; Liu Y; Nakshatri H
    Mol Cell Biol; 2008 Dec; 28(24):7487-503. PubMed ID: 18838536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
    Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
    Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations.
    Dogruluk T; Tsang YH; Espitia M; Chen F; Chen T; Chong Z; Appadurai V; Dogruluk A; Eterovic AK; Bonnen PE; Creighton CJ; Chen K; Mills GB; Scott KL
    Cancer Res; 2015 Dec; 75(24):5341-54. PubMed ID: 26627007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phosphatidylinositol 3-kinase (PI3KCA) oncogene mutation analysis and gene expression profiling in primary breast cancer patients.
    Kandula M; Chennaboina KK; Ys AR; Raju S
    Asian Pac J Cancer Prev; 2013; 14(9):5067-72. PubMed ID: 24175777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers.
    Fang WL; Huang KH; Lan YT; Lin CH; Chang SC; Chen MH; Chao Y; Lin WC; Lo SS; Li AF; Wu CW; Chiou SH; Shyr YM
    Oncotarget; 2016 Feb; 7(5):6201-20. PubMed ID: 26701847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
    Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
    Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.